{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:32:01Z","timestamp":1768512721377,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.beha.2005.01.033","type":"journal-article","created":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T21:56:07Z","timestamp":1165010167000},"page":"169-189","source":"Crossref","is-referenced-by-count":70,"title":["Risks and side effects of therapy with plasma and plasma fractions"],"prefix":"10.1016","volume":"19","author":[{"given":"Sheila","family":"MacLennan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.J.","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2005.01.033_bib1","series-title":"Handbook of Transfusion Medicine","year":"2001"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1423-0410.1995.tb02590.x","article-title":"Virally inactivated fresh frozen plasma","volume":"69","author":"Williamson","year":"1995","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5858\/2003-127-0316-ATR","article-title":"Allergic transfusion reactions: an evaluation of 273 consecutive reactions","volume":"127","author":"Domen","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.beha.2005.01.033_bib4","series-title":"Transfusion Reactions","first-page":"83","article-title":"Allergic and anaphylactic reactions","author":"Vamvakas","year":"2001"},{"key":"10.1016\/j.beha.2005.01.033_bib5","unstructured":"Stainsby D, Cohen H, Jones H et al. Serious Hazards of Transfusion (SHOT) Annual Report 2003. Manchester Blood Centre: Serious Hazards of Transfusion Office; 2004."},{"issue":"1","key":"10.1016\/j.beha.2005.01.033_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1537-2995.1975.15175103503.x","article-title":"Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature","volume":"15","author":"Pineda","year":"1975","journal-title":"Transfusion"},{"issue":"25","key":"10.1016\/j.beha.2005.01.033_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199106203242506","article-title":"Anaphylaxis","volume":"324","author":"Bochner","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood.V95.4.1138.004k27_1138_1143","article-title":"Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions","volume":"95","author":"Koda","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2005.01.033_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1423-0410.1980.tb02368.x","article-title":"Presence of aspirin in blood units","volume":"38","author":"Sharon","year":"1980","journal-title":"Vox Sang"},{"issue":"1","key":"10.1016\/j.beha.2005.01.033_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-82-1-58","article-title":"Anaphylaxis from the product(s) of ethylene oxide gas","volume":"82","author":"Poothullil","year":"1975","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib11","first-page":"229","article-title":"Anaphylaxis during anaesthesia: diagnosis and treatment","volume":"55","author":"Soetens","year":"2004","journal-title":"Acta Anaesthesiol Belg"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V84.6.2031.2031","article-title":"Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions","volume":"84","author":"Sandler","year":"1994","journal-title":"Blood"},{"issue":"7563","key":"10.1016\/j.beha.2005.01.033_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(68)90527-8","article-title":"Anaphylactoid transfusion reactions associated with anti-IgA","volume":"2","author":"Vyas","year":"1968","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.beha.2005.01.033_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM196905082801912","article-title":"Isoimmune anti-IgA causing anaphylactoid transfusion reactions","volume":"280","author":"Vyas","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2005.01.033_bib15","unstructured":"Boralessa H. Investigation and clinical management of suspected reactions to IgA. NBS Clinical Policies Group, 2003. online at http:\/\/www.blood.co.uk\/hospitals\/guidelines\/index.htm."},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1537-2995.2004.03290.x","article-title":"Significant numbers of apheresis-derived group O platelet units have \u2018high-titer\u2019 anti-A\/A,B: implications for transfusion policy","volume":"44","author":"Josephson","year":"2004","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1537-2995.1985.25686071434.x","article-title":"Diagnostic and pathogenetic considerations in transfusion-related acute lung injury","volume":"25","author":"Popovsky","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.beha.2005.01.033_bib18","unstructured":"Asher D, Atterbury CLJ, Chapman C et al. Serious Hazards of Transfusion Annual Report 2000\u20132001. Manchester: SHOT Steering Group, 2002."},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2002-03-0958","article-title":"Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors","volume":"101","author":"Silliman","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1537-2995.2001.41030312.x","article-title":"Transfusion-related acute lung injury: femme fatale?","volume":"41","author":"Popovsky","year":"2001","journal-title":"Transfusion"},{"issue":"supplement 3","key":"10.1016\/j.beha.2005.01.033_bib21","first-page":"4","article-title":"Prevalence of HLA and HNA antibodies in donors: correlation with pregnancy and transfusion history","volume":"87","author":"MacLennan","year":"2004","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2141.1999.01357.x","article-title":"Transfusion-related acute lung injury","volume":"105","author":"Kopko","year":"1999","journal-title":"Br J Haematol"},{"issue":"6261","key":"10.1016\/j.beha.2005.01.033_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.282.6261.379","article-title":"Pulmonary oedema after transfusion with fresh frozen plasma","volume":"282","author":"O'Connor","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.beha.2005.01.033_bib24","series-title":"Transfusion Reactions","first-page":"255","article-title":"Circulatory overload","author":"Popovsky","year":"2001"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0887-7963(88)70035-8","article-title":"Citrate toxicity during massive blood transfusion","volume":"2","author":"Dzik","year":"1988","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.beha.2005.01.033_bib26","series-title":"Some unfavourable effects of transfusion. Blood Transfusion in Clinical Medicine","author":"Mollison","year":"1997"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0195-6701(81)90043-8","article-title":"Operating theatre water-baths as a cause of pseudomonas septicaemia","volume":"2","author":"Casewell","year":"1981","journal-title":"J Hosp Infect"},{"issue":"26","key":"10.1016\/j.beha.2005.01.033_bib28","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","article-title":"The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study","volume":"334","author":"Schreiber","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1423-0410.2003.00296.x","article-title":"Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993\u20132001","volume":"84","author":"Soldan","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.beha.2005.01.033_bib30","doi-asserted-by":"crossref","unstructured":"Barbara, JAJ. The rationale for pathogen-inactivated treatment of blood components. Int J Hematol 2004; 80: 311\u2013316.","DOI":"10.1532\/IJH97.04120"},{"issue":"1","key":"10.1016\/j.beha.2005.01.033_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1537-2995.2001.41010130.x","article-title":"Parvovirus B19: implications for transfusion medicine. Summary of a workshop","volume":"41","author":"Brown","year":"2001","journal-title":"Transfusion"},{"issue":"9234","key":"10.1016\/j.beha.2005.01.033_bib32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(00)02719-7","article-title":"Transmission of BSE by blood transfusion in sheep","volume":"356","author":"Houston","year":"2000","journal-title":"Lancet"},{"issue":"Pt 11","key":"10.1016\/j.beha.2005.01.033_bib33","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1099\/0022-1317-83-11-2897","article-title":"Transmission of prion diseases by blood transfusion","volume":"83","author":"Hunter","year":"2002","journal-title":"J Gen Virol"},{"issue":"9407","key":"10.1016\/j.beha.2005.01.033_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt\u2013Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"issue":"9433","key":"10.1016\/j.beha.2005.01.033_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient","volume":"364","author":"Peden","year":"2004","journal-title":"Lancet"},{"issue":"9433","key":"10.1016\/j.beha.2005.01.033_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.beha.2005.01.033_bib37","first-page":"825","article-title":"Blood transfusion and tropical disease","volume":"69","author":"Bruce-Chwatt","year":"1972","journal-title":"Trop Dis Bull"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1537-2995.1991.31691306255.x","article-title":"Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries","volume":"31","author":"Schmunis","year":"1991","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.beha.2005.01.033_bib39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1046\/j.1537-2995.2003.00483.x","article-title":"Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?","volume":"43","author":"Williamson","year":"2003","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-2141.2000.02019.x","article-title":"Viral inactivation of fresh frozen plasma","volume":"109","author":"Pamphilon","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.01.033_bib41","series-title":"Guidelines for the Blood Transfusion Services in the United Kingdom","year":"2002"},{"issue":"12","key":"10.1016\/j.beha.2005.01.033_bib42","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1046\/j.1537-2995.2001.41121548.x","article-title":"Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate","volume":"41","author":"Atance","year":"2001","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1423-0410.1999.7740210.x","article-title":"Clinical tolerance of methylene blue virus-inactivated plasma. A randomised crossover trial in 12 healthy human volunteers","volume":"77","author":"Simonsen","year":"1999","journal-title":"Vox Sang"},{"issue":"supplement","key":"10.1016\/j.beha.2005.01.033_bib44","first-page":"541a","article-title":"Pathogen inactivation of plasma using Helinx technology conserves the activity of coagulation, anticoagulation and fibrinolytic proteins","volume":"98","author":"Pinkoski","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.033_bib45","series-title":"Monograph on COBE BCT Pathogen Inactivation Technology","author":"Corbin","year":"1999"},{"issue":"supplement 2","key":"10.1016\/j.beha.2005.01.033_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF03165125","article-title":"Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer","volume":"76","author":"Corbin","year":"2002","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.beha.2005.01.033_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.0958-7578.2004.00528.x","article-title":"Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration","volume":"14","author":"Hornsey","year":"2004","journal-title":"Transfus Med"},{"issue":"10","key":"10.1016\/j.beha.2005.01.033_bib48","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1046\/j.1537-2995.2003.00544.x","article-title":"The role of toxicology assessment in transfusion medicine","volume":"43","author":"Ciaravino","year":"2003","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.beha.2005.01.033_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF01703949","article-title":"No evidence for neoantigens in human plasma after photochemical virus inactivation","volume":"65","author":"Mohr","year":"1992","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1423-0410.2003.00351.x","article-title":"Preclinical safety profile of plasma prepared using the INTERCEPT blood system","volume":"85","author":"Ciaravino","year":"2003","journal-title":"Vox Sang"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib51","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2141.1996.d01-1836.x","article-title":"Plasma exchange with solvent\u2013detergent-treated plasma of resistant thrombotic thrombocytopenic purpura","volume":"94","author":"Harrison","year":"1996","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/1098-1101(2000)15:3<169::AID-JCA2>3.0.CO;2-R","article-title":"Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent\/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?","volume":"15","author":"Flamholz","year":"2000","journal-title":"J Clin Apheresis"},{"issue":"5","key":"10.1016\/j.beha.2005.01.033_bib53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2141.2003.04360.x","article-title":"Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura","volume":"121","author":"Yarranton","year":"2003","journal-title":"Br J Haematol"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.01.033_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1423-0410.1998.tb05479.x","article-title":"Hemovigilance: clinical tolerance of solvent\u2013detergent treated plasma","volume":"74","author":"Baudoux","year":"1998","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","article-title":"Adverse effects of intravenous immunoglobulin therapy","volume":"21","author":"Nydegger","year":"1999","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"issue":"6 supplement 5","key":"10.1016\/j.beha.2005.01.033_bib58","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.6_Suppl_5.S2","article-title":"Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00043426-199024000-00015","article-title":"Differences in immunoglobulin preparations for intravenous use: a comparison of six products","volume":"12","author":"Greenbaum","year":"1990","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.beha.2005.01.033_bib60","series-title":"Characterisation of Complement Anaphylatoxins and their Biological Responses. The Human Complement System in Health and Disease","author":"Ember","year":"1998"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1537-2995.2001.41020264.x","article-title":"Transfusion-related acute lung injury after the infusion of IVIG","volume":"41","author":"Rizk","year":"2001","journal-title":"Transfusion"},{"issue":"7345","key":"10.1016\/j.beha.2005.01.033_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/bmj.324.7345.1056","article-title":"Intravenous immunoglobulin increases risk of thrombotic events","volume":"324","author":"Gottlieb","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archneur.1993.00540020015010","article-title":"Acute renal failure resulting from intravenous immunoglobulin therapy","volume":"50","author":"Tan","year":"1993","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib64","first-page":"765","article-title":"Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report","volume":"15","author":"Winward","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00045391-199811000-00008","article-title":"Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise?","volume":"5","author":"Perazella","year":"1998","journal-title":"Am J Ther"},{"key":"10.1016\/j.beha.2005.01.033_bib66","series-title":"Important Drug Information: Immune Globulin Intravenous","author":"Epstein","year":"1999"},{"issue":"3","key":"10.1016\/j.beha.2005.01.033_bib67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/clind\/15.3.564","article-title":"Aseptic meningitis following administration of intravenous immune globulin","volume":"15","author":"Molina","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.beha.2005.01.033_bib68","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1212\/WNL.42.8.1636-a","article-title":"Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"42","author":"Vera-Ramirez","year":"1992","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib69","first-page":"129","article-title":"Aseptic meningitis and intravenous gammaglobulin treatment","volume":"147","author":"Ozsoylu","year":"1993","journal-title":"Am J Dis Child"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3476(97)70355-X","article-title":"Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G","volume":"130","author":"Kattamis","year":"1997","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJM199201233260413","article-title":"Transient neutropenia induced by intravenous immune globulin","volume":"326","author":"Ben Chetrit","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib73","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0192-0561(99)00020-X","article-title":"Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming","volume":"21","author":"Berkovitch","year":"1999","journal-title":"Int J Immunopharmacol"},{"issue":"12","key":"10.1016\/j.beha.2005.01.033_bib74","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood.V82.12.3789.3789","article-title":"Hemolysis after high-dose intravenous Ig","volume":"82","author":"Thomas","year":"1993","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2005.01.033_bib75","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1537-2995.1986.26587020113.x","article-title":"Hemolysis following intravenous immune globulin therapy","volume":"26","author":"Copelan","year":"1986","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib76","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1537-2995.1986.26286152919.x","article-title":"Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma","volume":"26","author":"Wells","year":"1986","journal-title":"Transfusion"},{"issue":"8411","key":"10.1016\/j.beha.2005.01.033_bib77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0140-6736(84)91506-X","article-title":"Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin","volume":"2","author":"Lever","year":"1984","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beha.2005.01.033_bib78","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJM199412153312402","article-title":"Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin","volume":"331","author":"Bjoro","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2005.01.033_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0002-9343(88)90016-2","article-title":"Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency","volume":"84","author":"Bjorkander","year":"1988","journal-title":"Am J Med"},{"issue":"24","key":"10.1016\/j.beha.2005.01.033_bib80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infections through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2005.01.033_bib81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.beha.2005.01.033_bib82","series-title":"Handbook of Hemophilia","article-title":"Complications to infusion therapy","author":"Vermylen","year":"1975"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib83","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.1999.01268.x","article-title":"Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97","volume":"104","author":"Yee","year":"1999","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2005.01.033_bib84","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.beha.2005.01.033_bib85","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977\u201399","volume":"2","author":"Darby","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib86","first-page":"912","article-title":"Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors","volume":"80","author":"Key","year":"1998","journal-title":"Thromb Haemost"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.01.033_bib87","first-page":"S115","article-title":"Clinical experience with activated factor VII: focus on safety aspects","volume":"9","author":"Roberts","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.beha.2005.01.033_bib88","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0038-1656122","article-title":"Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA study group. Factor eight bypassing activity","volume":"77","author":"Negrier","year":"1997","journal-title":"Thromb Haemost"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.01.033_bib89","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0049-3848(99)00079-1","article-title":"Thrombogenicity of prothrombin complex concentrates","volume":"95","author":"Kohler","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.beha.2005.01.033_bib90","series-title":"Thrombosis and Haemorrhage","first-page":"773","article-title":"Other coagulation factor deficiencies","author":"Roberts","year":"1998"},{"issue":"7153","key":"10.1016\/j.beha.2005.01.033_bib91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.317.7153.235","article-title":"Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane injuries group albumin reviewers","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.beha.2005.01.033_bib92","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","article-title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","volume":"350","author":"Finfer","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2005.01.033_bib93","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.0041-1132.2004.00422.x","article-title":"Why do physicians request fresh frozen plasma?","volume":"44","author":"Dzik","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.beha.2005.01.033_bib94","unstructured":"Cardigan R, Prowse CV, Williamson LM. Leucocyte depletion and pathogen inactivation. In Barbara JAJ, Regan F, Contreras MC (ed.) Transfusion Microbiology. Cambridge: Cambridge University Press; in press."}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:51:44Z","timestamp":1628146304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692605000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1521692605000344"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2005.01.033","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}